Rocephin Ceftriaxone Sodium for Injection

1. Indications and Usage
Therapeutic Use: Treatment of moderate to severe infections caused by susceptible bacteria, including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, bone and joint infections, septicemia, bacterial meningitis, and disseminated Lyme disease.
Prophylactic Use: Preoperative prophylaxis to reduce the risk of postoperative infections in surgical procedures.
Gonorrhea: Treatment of uncomplicated and disseminated gonorrhea caused by Neisseria gonorrhoeae.
2. Dosage and Administration
Adults: The usual dosage is 1–2 g administered once every 24 hours. For severe or life-threatening infections, the total daily dose may be increased to 4 g, administered as 2 g every 12 hours.
Pediatrics: The usual pediatric dosage is 50–75 mg/kg/day administered once every 24 hours or divided into two equal doses. For bacterial meningitis, 100 mg/kg/day may be used.
Renal and Hepatic Impairment: No dosage adjustment is typically required for patients with renal impairment unless there is concurrent hepatic dysfunction.
Administration: Can be administered via intramuscular injection or intravenous infusion. When reconstituting for IV use, it should be infused over 30 minutes.
3. Mechanism of Action
Cell Wall Inhibition: Ceftriaxone is a bactericidal agent that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).
Spectrum: It demonstrates broad-spectrum activity against many Gram-positive and Gram-negative bacteria and is highly stable against many beta-lactamases.
4. Safety and Warnings
Hypersensitivity: Severe and occasionally fatal hypersensitivity reactions have been reported. It should not be used in patients with a history of immediate hypersensitivity to cephalosporins.
Neonatal Use: It should not be administered to neonates (especially premature infants) who are hyperbilirubinemic or require calcium-containing IV solutions.
Biliary Pseudolithiasis: Reversible biliary sludge has been reported, which may mimic gallstones.
Coagulation: Cephalosporins may interfere with vitamin K metabolism, potentially increasing the risk of bleeding, especially in malnourished or debilitated patients.
5. Adverse Reactions and Clinical Research
Common: Gastrointestinal symptoms such as diarrhea, nausea, vomiting, and injection site reactions.
Serious: Hypersensitivity reactions (including anaphylaxis), eosinophilia, transient elevation of liver enzymes, and biliary sludge.
Clinical Research: Pivotal clinical trials have demonstrated high efficacy and safety in treating community-acquired surgical and medical infections.
6. Drug Interactions
Calcium-Containing Solutions: Concomitant use in neonates can cause fatal precipitation. Caution is advised in other patient populations.
Probenecid: Does not significantly alter the renal excretion or half-life of ceftriaxone.
Warfarin: May enhance the anticoagulant effect; prothrombin time should be monitored.
Aminoglycosides: Concomitant use may enhance the risk of nephrotoxicity.
7. Pharmaceutical Information
Active Ingredient: Ceftriaxone Sodium.
Excipients: Sodium acetate and/or acetic acid.
Appearance: White or yellowish-white lyophilized powder or crystals.
Storage: Store in a well-closed container, protected from light and moisture.